Mylan reported a loss of $119.8 million in the third quarter vs. a profit of $428.6 million a year earlier, reflecting the proposed $465 million settlement with the U.S. Justice Department over the generic drugmaker's EpiPen allergy injector.
Per-share results showed a loss of 23 cents vs. a profit of 83 cents last year.
Excluding litigation costs and other adjustments, per-share profits were $1.38, down 3 percent from a year earlier and below Wall Street's consensus estimate of $1.45 per share.
Revenue for the three months ended that Sept. 30 was $3.06 billion, up 13 percent from $2.7 billion.
